[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0101243A1 - Új eprosartan készítmények - Google Patents

Új eprosartan készítmények

Info

Publication number
HUP0101243A1
HUP0101243A1 HU0101243A HUP0101243A HUP0101243A1 HU P0101243 A1 HUP0101243 A1 HU P0101243A1 HU 0101243 A HU0101243 A HU 0101243A HU P0101243 A HUP0101243 A HU P0101243A HU P0101243 A1 HUP0101243 A1 HU P0101243A1
Authority
HU
Hungary
Prior art keywords
eprosartan
compositions
particle size
well
relates
Prior art date
Application number
HU0101243A
Other languages
English (en)
Inventor
Gopadi M. Venkatesh
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP0101243A1 publication Critical patent/HUP0101243A1/hu
Publication of HUP0101243A3 publication Critical patent/HUP0101243A3/hu
Publication of HU228574B1 publication Critical patent/HU228574B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány az (E)-2-([2-butil-1-(4-karboxi-benzil)-1H-5-imidazolil]-metilén)-3-(2-tienil)-propionsav (eprosartan) vagy mezilátsója(eprosartan-mezilát) új készítményeire, valamint a készítményekangiotenzin II (AII) receptorok terápiás blokkolására, valaminthipertenzió, szívszélhűdés és veseelégtelenség kezelésére szolgálóalkalmazására vonatkozik. Közelebbről a találmány olyan, eprosartantvagy sóját, szolvátját vagy hidrátját tartalmazó, szemcsés formábanlévő új kompozíciókra vonatkozik, amely kompozíciók szemcseméret-eloszlása olyan, hogy a térfogati átlagátmérő középértéke 450-től 700nm-ig terjed. Az előbbieknek megfelelő, szabályozott szemcseméretűkompozíciókban az eprosartan fokozott biológiai hasznosíthatósággalrendelkezik. Ó
HU0101243A 1998-03-11 1999-03-11 Novel compositions of eprosartan HU228574B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (3)

Publication Number Publication Date
HUP0101243A1 true HUP0101243A1 (hu) 2002-05-29
HUP0101243A3 HUP0101243A3 (en) 2005-09-28
HU228574B1 HU228574B1 (en) 2013-04-29

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101243A HU228574B1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Country Status (21)

Country Link
EP (1) EP1061803B1 (hu)
JP (1) JP2002506010A (hu)
KR (1) KR20010041796A (hu)
CN (1) CN1299235A (hu)
AT (1) ATE508633T1 (hu)
AU (1) AU757547B2 (hu)
BR (1) BR9908691A (hu)
CA (1) CA2323363C (hu)
CY (1) CY1111738T1 (hu)
CZ (1) CZ303067B6 (hu)
DK (1) DK1061803T3 (hu)
ES (1) ES2366394T3 (hu)
HU (1) HU228574B1 (hu)
IL (1) IL138345A (hu)
NO (1) NO331207B1 (hu)
NZ (1) NZ506700A (hu)
PL (1) PL192545B1 (hu)
SI (1) SI1061803T1 (hu)
TR (1) TR200002646T2 (hu)
WO (1) WO1999045779A1 (hu)
ZA (1) ZA991922B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
BR0110079A (pt) * 2000-04-12 2002-12-31 Novartis Ag Combinação de compostos orgânicos
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
CA2513729A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
BRPI0512379A (pt) * 2004-06-23 2008-03-11 Solvay Pharm Gmbh composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CZ293345B6 (cs) * 1996-03-29 2004-04-14 Smithkline Beecham Corporation Dihydrát monomethansulfonatu kyseliny (E)-alfa-[2-n-butyl-1-[(4-karboxyfenyl)methyl]-1H-imidazol-5-yl]methylen-2-thiofenpropionové
CZ296274B6 (cs) * 1997-08-06 2006-02-15 Smithkline Beecham Corporation Neutralizacní komplex arginyl-eprosartan, zpusob jeho prípravy a prostredek

Also Published As

Publication number Publication date
CA2323363A1 (en) 1999-09-16
AU757547B2 (en) 2003-02-27
CN1299235A (zh) 2001-06-13
EP1061803A4 (en) 2007-12-26
EP1061803B1 (en) 2011-05-11
CA2323363C (en) 2008-09-30
KR20010041796A (ko) 2001-05-25
PL192545B1 (pl) 2006-11-30
CY1111738T1 (el) 2015-10-07
NZ506700A (en) 2003-03-28
CZ20003288A3 (cs) 2001-03-14
HU228574B1 (en) 2013-04-29
EP1061803A1 (en) 2000-12-27
IL138345A (en) 2004-12-15
JP2002506010A (ja) 2002-02-26
ATE508633T1 (de) 2011-05-15
BR9908691A (pt) 2000-12-26
ZA991922B (en) 1999-09-13
CZ303067B6 (cs) 2012-03-21
TR200002646T2 (tr) 2001-01-22
HUP0101243A3 (en) 2005-09-28
ES2366394T3 (es) 2011-10-19
AU2890999A (en) 1999-09-27
SI1061803T1 (sl) 2011-09-30
WO1999045779A1 (en) 1999-09-16
NO331207B1 (no) 2011-10-31
PL343411A1 (en) 2001-08-13
NO20004502D0 (no) 2000-09-08
DK1061803T3 (da) 2011-08-29
IL138345A0 (en) 2001-10-31
NO20004502L (no) 2000-11-07

Similar Documents

Publication Publication Date Title
HUP0101243A1 (hu) Új eprosartan készítmények
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
JO2371B1 (en) 4-phenyl-pyridine derivatives
WO2003080024A3 (en) Nanoparticulate compositions of map kinase inhibitors
WO2004072033A3 (en) Pyrazoles and methods of making and using the same
HK1064099A1 (en) Platelet adp receptor inhibitors
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2001097851A3 (en) Compositions and methods to improve the oral absorption of antimicrobial agents
AU2003230691A1 (en) Nanoparticulate compositions of angiogenesis inhibitors
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
ID29930A (id) Senyawa-senyawa triazol dan penggunaannya
CA2416867A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
EA200701202A1 (ru) Препараты из наночастиц бензотиофена
WO2004082623A3 (en) Substituted piperidine compounds
AU2003228674A1 (en) Muscarinic antagonists
WO2003053399A3 (en) Methods for wet granulating azithromycin
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
SE9900079L (sv) Sätt att tillverka hårdmetall med en bimodal kornstorleksfördelning och som innehåller korntillväxthämmare
BR0111868A (pt) Composições farmacêuticas
WO2005033048A3 (en) Wnt pathway antagonists
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
SG162811A1 (en) Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds
WO2005065047A3 (en) Stable oral composition containing desloratadine

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees